公司概述
BioRestorative Therapies, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops therapeutic products and medical therapies utilizing cell and tissue protocols primarily involving adult stem cells. The company's strategic focus is on creating programs to treat disc and spine disease as well as metabolic disorders, utilizing a product pipeline that includes BRTX-100. In terms of scale, the company maintains a market capitalization of $6.11M, generates annual revenue of $359,700, and employs 13 individuals. These financial figures indicate that the company operates with a very small market capitalization relative to its revenue, characterizing it as a micro-cap entity with limited resources compared to larger industry peers. The low employee count of 13 suggests a lean organizational structure typical of early-stage biotechnology firms that are heavily reliant on intellectual property and research development rather than large-scale manufacturing or sales operations. The revenue figure of $359,700 reflects the nascent stage of commercialization or the specific focus on research and development phases typical for companies in this developmental sector. Consequently, the company's position is defined by its specialized focus on regenerative medicine technologies rather than broad-market product distribution.
财务健康
The company reported revenue of $359,700 over the trailing twelve months, while net income stood at -$14,241,975, resulting in an EBITDA of -$15,437,147. The substantial gap between the modest revenue of $359,700 and the significant net loss of -$14,241,975 reveals a cost structure dominated by high research and development expenses or operational overheads that far exceed current sales generation. Free cash flow is reported at -$6,200,023, which indicates that the company is burning cash rapidly and lacks the internal financial flexibility to fund operations without external capital injections. Analyzing the margins shows a gross margin of 93.4%, which suggests high value added per unit of revenue, yet this is offset by an operating margin of -19516.8% and a profit margin of 0.0%, highlighting severe operational inefficiencies or significant non-operating costs impacting the bottom line. The balance sheet shows cash holdings of $2.95M against total debt of $42,282, resulting in a debt-to-equity ratio of 11.85, which presents a complex picture of high leverage relative to equity despite low absolute debt levels. The current ratio stands at 0.84, indicating that current assets are insufficient to cover current liabilities, which points to potential short-term liquidity challenges if cash burn continues. Return on Equity is -320.5% and Return on Assets is -119.6%, metrics that reveal that management has not yet been effective at generating positive returns on the capital invested in the company. These negative return metrics underscore the high risk associated with the company's current financial trajectory and the difficulty in achieving profitability in the near term.
估值评估
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -0.46, implying that future earnings estimates are also negative and do not support a traditional earnings-based valuation multiple. The price-to-book ratio is 6.15, indicating that the market values the company's equity at a significant premium over its book value, a common phenomenon in biotechnology firms where intangible assets like patents and pipeline potential are not fully captured on the balance sheet. The price-to-sales ratio is 17.00, and the EV/EBITDA is -0.21; these alternative valuation metrics suggest that investors are pricing the stock based on revenue potential and asset backing rather than profitability, reflecting high expectations for future clinical success or market capture. The 52-week high is $2.04 and the 52-week low is $0.19, meaning the stock has experienced extreme volatility within a wide trading range over the past year. Without a specific current price provided in the facts, the valuation context suggests the stock trades at a high multiple of its sales given the lack of profit. The beta value is 0.27, which indicates that the stock price volatility is significantly lower than the broader market, suggesting low systematic risk relative to large-cap indices despite the high idiosyncratic risk inherent in the biotechnology sector.
Growth & Income
Revenue growth year-over-year is -54.7%, while earnings growth is N/A due to the company reporting a net loss; this implies that the company is currently contracting in terms of top-line revenue rather than expanding. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders but instead reinvests all available capital, however limited, into research and development or operational continuity. The absence of a dividend yield confirms that the company prioritizes capital retention to sustain its cash burn rate of -$6,200,023 and fund its pipeline of therapeutic products. Overall, the company presents a profile of negative revenue growth and no income distribution, characteristic of a pre-revenue or early-stage biotechnology company struggling with commercialization hurdles and high operational costs. The financial data illustrates a challenging environment where the company must navigate declining revenue while attempting to develop its stem cell-based therapies for spine and metabolic conditions. This growth and income profile highlights the speculative nature of the investment, where value is derived from potential future breakthroughs rather than current financial performance. The lack of earnings growth reinforces the need for external financing to survive the current cash burn phase.